Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) Tax Provisions (2022 - 2025)

Sutro Biopharma (STRO) has disclosed Tax Provisions for 4 consecutive years, with -$82000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 103.48% to -$82000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, down 87.59% year-over-year, with the annual reading at -$93000.0 for FY2025, 103.94% down from the prior year.
  • Tax Provisions hit -$82000.0 in Q4 2025 for Sutro Biopharma, down from -$18000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $15.8 million in Q4 2023 to a low of -$82000.0 in Q4 2025.
  • Historically, Tax Provisions has averaged $2.6 million across 4 years, with a median of $395000.0 in 2023.
  • Biggest five-year swings in Tax Provisions: plummeted 85.11% in 2024 and later tumbled 325.0% in 2025.
  • Year by year, Tax Provisions stood at $2.5 million in 2022, then skyrocketed by 532.6% to $15.8 million in 2023, then tumbled by 85.11% to $2.4 million in 2024, then crashed by 103.48% to -$82000.0 in 2025.
  • Business Quant data shows Tax Provisions for STRO at -$82000.0 in Q4 2025, -$18000.0 in Q2 2025, and $2.4 million in Q4 2024.